* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周二早盘升3.9%。
* 该公司此前公告称，TQB2102正在开展一项随机、开放、平行对照的III期临床试验，评价注射用TQB2102对比研究者选择的化疗在HER2低表达复发╱转移性乳腺癌中有效性和安全性，近期已完成全部受试者入组。
* 中国生物制药今年迄今涨10.8%，同期恒生指数.HSI上扬6.6%。
* 恒⽣⽣物科技指数.HSBIO盘中升3.2%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 杨淑祯)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.